Assessment of Interactions Between Methamphetamine and Aripiprazole - 1

This study is ongoing, but not recruiting participants.

Sponsored by:	National Institute on Drug Abuse (NIDA)
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00089440

Purpose

The purpose of this study is to assess the interactions between intravenous methamphetamine and aripiprazole.

Condition	Intervention	Phase
Amphetamine-Related Disorders	Drug: Aripiprazole	Phase I

MedlinePlus related topics: Methamphetamine

Drug Information available for: Aripiprazole Amphetamine Methamphetamine

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Placebo Control
Official Title:	Assessment of Interactions Between IV Methamphetamine and Aripiprazole

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Adverse effect measures
pharmacokinetic assessment

Estimated Enrollment:	17
Study Start Date:	June 2004
Estimated Study Completion Date:	March 2005

Detailed Description:

This is a double-blind, placebo-controlled human laboratory clinical pharmacology study to assess potential interactions between intravenous d-methamphetamine infusion and treatment with oral aripiprazole.

Eligibility

Ages Eligible for Study:	18 Years to 45 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Must meet DSM-4 criteria for methamphetamine abuse or dependence and are non-treatment seeking.
Ability to verbalize understanding of the consent form, able to provide written informed consent, and verbalize willingness to complete study procedures.

Exclusion Criteria:

Please contact the site for more information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00089440

Locations

United States, California
UCLA Integrated Substance Abuse Program
Los Angeles, California, United States, 90024
United States, New York
New York University, School of Medicine
New York, New York, United States, 10016

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

Investigators

Principal Investigator:

Thomas Newton, M.D.

University of California, Los Angeles

More Information

Study ID Numbers:	NIDA-MDS-0002-1
Study First Received:	August 5, 2004
Last Updated:	October 25, 2007
ClinicalTrials.gov Identifier:	NCT00089440
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Methamphetamine
Dopamine
Mental Disorders
Amphetamine-Related Disorders

Substance-Related Disorders
Disorders of Environmental Origin
Amphetamine
Aripiprazole

Additional relevant MeSH terms:

Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Tranquilizing Agents
Molecular Mechanisms of Pharmacological Action
Adrenergic Agents
Sympathomimetics
Adrenergic Uptake Inhibitors
Physiological Effects of Drugs
Psychotropic Drugs

Central Nervous System Depressants
Central Nervous System Stimulants
Antipsychotic Agents
Pharmacologic Actions
Autonomic Agents
Therapeutic Uses
Dopamine Agents
Peripheral Nervous System Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on January 14, 2009